Enantiomeric Separation via Preferential Crystallization
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
Current methods for resolving optical enantiomers of dihydro-1,3,5-triazine derivatives are energy-intensive and generate waste, requiring expensive chiral resolving agents and often result in incomplete enantiomeric purity.
Innovation Solution
The process involves preferential crystallization of racemic mixtures that form stable conglomerate salts, allowing for the isolation of optical enantiomers without a chiral resolving agent, using seeding and repetitive crystallization in suitable solvents like ethanol, achieving high enantiomeric excess and yield.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Manufacturing precision
If chiral resolving agents are used for enantiomeric separation, then enantiomeric purity is improved, but process cost and waste generation increase
Solution Approach 1:
The invention extracts and utilizes the natural conglomerate-forming property of the dihydro-1,3,5-triazine salts themselves, removing the need for external chiral resolving agents. The racemic mixture is directly crystallized as a conglomerate and separated by preferential crystallization, eliminating the substance (resolving agent) that causes waste and cost issues.
Solution Approach 2:
The dihydro-1,3,5-triazine salts perform their own separation function by forming conglomerates that can be separated by preferential crystallization. The substance itself provides the mechanism for enantiomeric separation without requiring external chiral agents, making the process self-sufficient and waste-free.
2Manufacturing precision
If conventional enantiomeric separation methods are used, then enantiomeric purity is achieved, but energy consumption increases
Solution Approach 1:
The invention utilizes the phase transition of preferential crystallization from the racemic mixture to separate enantiomers. By controlling crystallization conditions, one enantiomer preferentially crystallizes while the other remains in solution, achieving separation through this phase change rather than energy-intensive methods like distillation or repeated chromatography.
3Manufacturing precision
If chiral resolving agents are employed, then enantiomeric resolution is improved, but process complexity and cost increase
Solution Approach 1:
The invention removes the complex component (chiral resolving agent) from the separation system, simplifying the process to direct preferential crystallization of the racemic mixture as a conglomerate. This extraction of the resolving agent eliminates the need for complex addition, removal, and recovery steps.
4Manufacturing precision
If diastereomeric resolution is used, then enantiomeric separation is achieved, but yield is reduced due to incomplete recovery
Solution Approach 1:
The invention implements continuous recycling of the mother liquor containing the other enantiomer back into the preferential crystallization process. This continuous action ensures that both enantiomers are eventually recovered with high yield, eliminating the waste associated with discarding mother liquors in conventional diastereomeric resolution methods.
Applied Scientific Principles
This section explains which scientific principles are used to turn an abstract innovation direction into a practical engineering solution.
Function Achieved in This Case
This method enables efficient, energy-saving resolution of optical enantiomers with theoretical quantitative yield and reduced waste, using preferential crystallization to isolate enantiomers from racemic mixtures that crystallize as conglomerates, improving safety and reducing costs.
Implementation Method 1
it has been found that compounds of formula I can form stable conglomerate salts and that the optical enantiomers of these salts can be resolved by preferential crystallization
Implementation Method 2
the optical enantiomers of these salts can be resolved by preferential crystallization
Data Source
AI summary
A new process for the enantiomeric separation of racemic 3,6-dihydro-1,3,5-triazine derivatives for the treatment of disorders associated with insulin-resistance syndrome, by preferential crystallization.